drugset

drugset / Trial / NCT06214793

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

NCT06214793 ↗

Phase 2 Suspended 61 enrolled Megan Kruse, MD AnHeart Therapeutics Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of talectrectinib as treatment for Stage IV ILC with CDH1 mutation

Timeline

Start: 2026-10
Primary completion: 2030-01-01
Completion: 2030-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AB-106	Small molecule	600 mg	Oral

Indications